Caricamento...
Open-label pilot study of injectable naltrexone for cannabis dependence
BACKGROUND: There are no FDA-approved pharmacotherapies for cannabis use disorders (CUD), despite the evaluation of numerous medications. Notably, chronic dosing of oral naltrexone decreases self-administration of cannabis in human laboratory studies. OBJECTIVES: To test the feasibility of long-acti...
Salvato in:
| Pubblicato in: | Am J Drug Alcohol Abuse |
|---|---|
| Autori principali: | , , , , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
2018
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6082728/ https://ncbi.nlm.nih.gov/pubmed/29420073 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/00952990.2017.1423321 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|